EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients

Tristan L Lim iD, Kamaneh Montazeri, Eric Wehrenberg-Klee, Antoine Desilets, Rino Seedor, Marlana Orloff, Takami Sato, Michael Caplan, Mariam El-Ashmawy, Benjamin Izar, Shaheer Khan, Inderjit Mehmi und 6 weitere

The Oncologist · 01.10.2025 · 30 (10)

DOI: 10.1093/oncolo/oyaf323 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 29.09.2025. Verfasst von Tristan L Lim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Cancer Center, Massachusetts General Hospital, Boston, MA 02114, United States. Hauptthemen laut MEDLINE: Uveal Melanoma, Recombinant Fusion Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Mass General Cancer Center's Melanoma Program, Mass General Cancer Center’s Melanoma Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tebentafusp has significantly improved overall survival in HLA-A*02:01+ metastatic uveal melanoma (mUM) patients even in those with a best objective response of progressive disease. Thus, strategies to maintain tebentafusp therapy are critical. Here, we examine the efficacy and safety of adding concurrent local therapy (CLT) to tebentafusp upon radiological progression with tebentafusp alone. Patients and Methods This multicenter retrospective study included mUM patients treated with tebentafusp and CLT, consisting of extrahepatic soft tissue irradiation and liver-directed therapies (LDTs). Efficacy of target and nontarget sites were assessed per RECIST version 1.1. PFS with tebentafusp alone (PFS1) was compared to that after adding CLTs to tebentafusp upon progression (PFS1+PFS2). ctDNA responses were explored.

Results

Of the 30 eligible patients, 21 (70%) received concurrent LDT, 7 (23%) had extrahepatic irradiation, and 2 (7%) had both. The objective response rate (ORR) was 12% (95% CI, 3-32) for tebentafusp alone and 28% (95% CI, 14-47) after adding CLTs. The disease-control rate with tebentafusp alone was 44% (95% CI, 25-65) vs 63% (95% CI, 44-78) after CLT. Median PFS1 was 5.8 months (95% CI, 2.8-13.4), while median PFS1+PFS2 was 14.8 months (95% CI, 9.2-NA). CLT thereby allowed treatment beyond progression with tebentafusp for approximately 9 months. Two patients (66%) had decreased ctDNA with tebentafusp alone, while 4 (100%) had decreased ctDNA after CLT. There were no treatment discontinuations due to toxicities from tebentafusp with CLT.

Conclusions

CLT with tebentafusp was well-tolerated, extending the duration of tebentafusp benefit in a highly selected mUM population. This merits further studies to assess clinical utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uveal MelanomaRecombinant Fusion ProteinsAdultAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisRetrospective Studies

Stichwörter der Autor:innen

Uveal melanomaconcurrent local therapiesctDNAtebentafusp

Substanzen

tebentafuspRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Mass General Cancer Center, Massachusetts General Hospital, Boston, MA 02114, United States.
  • Department of Interventional Radiology, Massachusetts General Hospital, Boston, MA 02114, United States.
  • Memorial Sloan Kettering Cancer Center, New York City, NY 10065, United States.
  • Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York City, NY 10032, United States.
  • Northwell Health Cancer Institute, New Hyde Park, NY 11042, United States.

ORCID-Profile: Tristan L Lim, Omid Hamid, Ryan J Sullivan

Förderung

  • NCI NIH HHS
  • Mass General Cancer Center's Melanoma Program
  • Mass General Cancer Center’s Melanoma Program

Zitieren

APA

Lim, T. L., Montazeri, K., Wehrenberg-Klee, E., Desilets, A., Seedor, R., Orloff, M., Sato, T., Caplan, M., El-Ashmawy, M., Izar, B., Khan, S., Mehmi, I., Lawless, A., Hong, T. S., Hamid, O., Carvajal, R. D., Shoushtari, A., & Sullivan, R. J. (2025). Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist, 30(10). https://doi.org/10.1093/oncolo/oyaf323

Vancouver

Lim TL, Montazeri K, Wehrenberg-Klee E, Desilets A, Seedor R, Orloff M, et al. Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist. 2025;30(10). doi:10.1093/oncolo/oyaf323

BibTeX
@article{Lim2025,
  author = {Lim, Tristan L and Montazeri, Kamaneh and Wehrenberg-Klee, Eric and Desilets, Antoine and Seedor, Rino and Orloff, Marlana and Sato, Takami and Caplan, Michael and El-Ashmawy, Mariam and Izar, Benjamin and Khan, Shaheer and Mehmi, Inderjit and Lawless, Aleigha and Hong, Theodore S and Hamid, Omid and Carvajal, Richard D and Shoushtari, Alexander and Sullivan, Ryan J},
  title = {Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {10},
  doi = {10.1093/oncolo/oyaf323}
}
Kostenlos starten →